ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors

Inclusion Criteria

• Participants with advanced solid tumor that is not amenable to surgical resection or other approved therapeutic options.
• Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 to 2.
• Participants must have measurable disease per Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1 or disease evaluable by assessment of tumor antigens:
• Participants with non-evaluable or non-measurable cancer are eligible if they have a confirmed increase in tumor antigens >=2 x upper limit of normal (ULN).
• All participants must consent to provide archived diagnostic formalin-fixed paraffin embedded (FFPE) tumor tissue and on study biopsies.
• Participant has adequate bone marrow, renal, hepatic and cardiac function.
• Women of childbearing potential must have a negative serum pregnancy test within 14 days prior to initiation of treatment.

Exclusion Criteria

• Participant has received anticancer therapy or any investigational therapy within a period of 21 days prior to the first dose of ABBV-085.
• Uncontrolled metastases to the central nervous system (CNS). Participants with brain metastases are eligible provided they have shown clinical and radiographic stable disease for at least 4 weeks after definitive therapy and have not used steroids for at least 4 weeks prior to first dose of ABBV-085.
• Unresolved adverse events >= Grade 2 from prior anticancer therapy, except for alopecia.
• Participant has ongoing hemolysis.
• Major surgery within <=28 days prior to the first dose of ABBV-085.
• Clinically significant uncontrolled condition(s).
• Participant has history of major immunologic reaction to any auristatin-based and /or Immunoglobulin G (IgG) containing agent.